Nkarta, Inc. NKTX
1.35 USD -0.24 (-15.09%)
At closeNov 11, 2026, 4:04 AM EST
1.34 -0.01 -0.74%
Pre-market · Nov 11, 4:04 AM ET
1.30 Day range 1.54
1.13 52-week range 3.72
- YTD
- -27.03%
- 1 year
- -32.84%
News
seekingalpha.com Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript Nkarta, Inc. ( NKTX ) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis November 9, 2026 8:00 AM EST Company Participants Paul Hastings - CEO & Director Shawn Rose - Chief…
benzinga.com Nkarta Reports Initial Clinical Data For NKX019 Demonstrating Early Efficacy And Favorable Tolerability In Autoimmune Disease Trial In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in…
globenewswire.com Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com Nkarta To Host Webcast On November 9 To Review Initial Clinical Data From Ntrust Program Evaluating NKX019 In Myositis And Systemic Sclerosis Being Presented At ACR Convergence 2026 Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast…
globenewswire.com Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…- benzinga.com Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 55.17 percent decrease over losses of $(0.29) per…
globenewswire.com Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
benzinga.com HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12 HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $12.